Cargando…

Multidrug-resistant bacteria compensate for the epistasis between resistances

Mutations conferring resistance to antibiotics are typically costly in the absence of the drug, but bacteria can reduce this cost by acquiring compensatory mutations. Thus, the rate of acquisition of compensatory mutations and their effects are key for the maintenance and dissemination of antibiotic...

Descripción completa

Detalles Bibliográficos
Autores principales: Moura de Sousa, Jorge, Balbontín, Roberto, Durão, Paulo, Gordo, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395140/
https://www.ncbi.nlm.nih.gov/pubmed/28419091
http://dx.doi.org/10.1371/journal.pbio.2001741
_version_ 1783229821794385920
author Moura de Sousa, Jorge
Balbontín, Roberto
Durão, Paulo
Gordo, Isabel
author_facet Moura de Sousa, Jorge
Balbontín, Roberto
Durão, Paulo
Gordo, Isabel
author_sort Moura de Sousa, Jorge
collection PubMed
description Mutations conferring resistance to antibiotics are typically costly in the absence of the drug, but bacteria can reduce this cost by acquiring compensatory mutations. Thus, the rate of acquisition of compensatory mutations and their effects are key for the maintenance and dissemination of antibiotic resistances. While compensation for single resistances has been extensively studied, compensatory evolution of multiresistant bacteria remains unexplored. Importantly, since resistance mutations often interact epistatically, compensation of multiresistant bacteria may significantly differ from that of single-resistant strains. We used experimental evolution, next-generation sequencing, in silico simulations, and genome editing to compare the compensatory process of a streptomycin and rifampicin double-resistant Escherichia coli with those of single-resistant clones. We demonstrate that low-fitness double-resistant bacteria compensate faster than single-resistant strains due to the acquisition of compensatory mutations with larger effects. Strikingly, we identified mutations that only compensate for double resistance, being neutral or deleterious in sensitive or single-resistant backgrounds. Moreover, we show that their beneficial effects strongly decrease or disappear in conditions where the epistatic interaction between resistance alleles is absent, demonstrating that these mutations compensate for the epistasis. In summary, our data indicate that epistatic interactions between antibiotic resistances, leading to large fitness costs, possibly open alternative paths for rapid compensatory evolution, thereby potentially stabilizing costly multiple resistances in bacterial populations.
format Online
Article
Text
id pubmed-5395140
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53951402017-05-04 Multidrug-resistant bacteria compensate for the epistasis between resistances Moura de Sousa, Jorge Balbontín, Roberto Durão, Paulo Gordo, Isabel PLoS Biol Research Article Mutations conferring resistance to antibiotics are typically costly in the absence of the drug, but bacteria can reduce this cost by acquiring compensatory mutations. Thus, the rate of acquisition of compensatory mutations and their effects are key for the maintenance and dissemination of antibiotic resistances. While compensation for single resistances has been extensively studied, compensatory evolution of multiresistant bacteria remains unexplored. Importantly, since resistance mutations often interact epistatically, compensation of multiresistant bacteria may significantly differ from that of single-resistant strains. We used experimental evolution, next-generation sequencing, in silico simulations, and genome editing to compare the compensatory process of a streptomycin and rifampicin double-resistant Escherichia coli with those of single-resistant clones. We demonstrate that low-fitness double-resistant bacteria compensate faster than single-resistant strains due to the acquisition of compensatory mutations with larger effects. Strikingly, we identified mutations that only compensate for double resistance, being neutral or deleterious in sensitive or single-resistant backgrounds. Moreover, we show that their beneficial effects strongly decrease or disappear in conditions where the epistatic interaction between resistance alleles is absent, demonstrating that these mutations compensate for the epistasis. In summary, our data indicate that epistatic interactions between antibiotic resistances, leading to large fitness costs, possibly open alternative paths for rapid compensatory evolution, thereby potentially stabilizing costly multiple resistances in bacterial populations. Public Library of Science 2017-04-18 /pmc/articles/PMC5395140/ /pubmed/28419091 http://dx.doi.org/10.1371/journal.pbio.2001741 Text en © 2017 Moura de Sousa et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Moura de Sousa, Jorge
Balbontín, Roberto
Durão, Paulo
Gordo, Isabel
Multidrug-resistant bacteria compensate for the epistasis between resistances
title Multidrug-resistant bacteria compensate for the epistasis between resistances
title_full Multidrug-resistant bacteria compensate for the epistasis between resistances
title_fullStr Multidrug-resistant bacteria compensate for the epistasis between resistances
title_full_unstemmed Multidrug-resistant bacteria compensate for the epistasis between resistances
title_short Multidrug-resistant bacteria compensate for the epistasis between resistances
title_sort multidrug-resistant bacteria compensate for the epistasis between resistances
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395140/
https://www.ncbi.nlm.nih.gov/pubmed/28419091
http://dx.doi.org/10.1371/journal.pbio.2001741
work_keys_str_mv AT mouradesousajorge multidrugresistantbacteriacompensatefortheepistasisbetweenresistances
AT balbontinroberto multidrugresistantbacteriacompensatefortheepistasisbetweenresistances
AT duraopaulo multidrugresistantbacteriacompensatefortheepistasisbetweenresistances
AT gordoisabel multidrugresistantbacteriacompensatefortheepistasisbetweenresistances